Sugemalimab
- L01FF11 (WHO)
- 2256084-03-2
- DB16641
- 90IQR2I6TR
- D12750
Sugemalimab is an experimental monoclonal antibody intended for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy.[1] It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands.[1]
It is a fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities.[2] Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1).[2] This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.[2] PD-L1 is overexpressed by many human cancer cell types.[2] PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion.[2] PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.[2] Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.[2]
Society and culture
Legal status
In May 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cejemly, intended for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy.[1][3] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH.[1]
Names
Sugemalimab is the international nonproprietary name.[4]
References
- ^ a b c d "Cejemly EPAR". European Medicines Agency. 30 May 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g "Sugemalimab (Code C154550)". NCI Thesaurus. 29 April 2024. Retrieved 1 June 2024.
This article incorporates text from this source, which is in the public domain.
- ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024". European Medicines Agency (Press release). 31 May 2024. Retrieved 13 June 2024.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.
- v
- t
- e
Receptor tyrosine kinase | |
---|---|
Others for solid tumors | |
Leukemia/lymphoma | |
Other |
|
Receptor tyrosine kinase |
|
---|---|
Non-receptor |
- fusion protein against VEGF (Aflibercept)
- proapoptotic peptide against ANXA2 and prohibitin (Adipotide)
- exotoxin against IL-2 (Denileukin diftitox)
- mTOR inhibitors
- hedgehog inhibitors
- CDK inhibitors
- KRAS inhibitors
- Cabozantinib
- Capmatinib
- Entrectinib
- Erdafitinib
- Gilteritinib
- Larotrectinib
- Lenvatinib
- Masitinib
- Midostaurin
- Nintedanib
- Pazopanib
- Pemigatinib
- Pexidartinib
- Quizartinib
- Regorafenib
- Ripretinib
- Sorafenib
- Sunitinib
- Tebentafusp
- Tepotinib
- Vandetanib
- Venetoclax
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e